This thing with the blood clots is bothering me a bit, although I know the risk is small. One thing I wonder is what the risks are like with the other vaccines, in particular Sputnik, which I understand is a similar type of vaccine to the Oxford AstraZenica vaccine. I think European leaders have successfully eroded confidence in the AstraZenica vaccine, probably world wide.
On the risks, review my post from Wednesday:
https://www.cyclechat.net/threads/covid-vaccine.267960/page-224#post-6366282
I mused a fortnight ago whether there was similar experience of CVT with the Pfizer/BioNTech vaccine (or Moderna). I agree that the damage of reacting with bans on the slightest concern misses the disproportionate impact on vaccine acceptance and therefore will result in thousands of lives lost and a significant delay to the return to social and economic 'life'. This is the sensible balance that the EMA considers in its continuance of temporary approval to use, disregarded by EU members, recognising that the threat to the individual from COVID-19 is an order of magnitude greater than any causality-unproven side effect. It's still possible that there is a causal link.
The vast majority of these adverse CVT experiences, some fatal, are reported in women of child bearing potential, a proportion of whom will be on the pill (non-Catholic countries). This younger female cohort will have mostly been vaccinated with Ox-AZ so you'd expect the miniscule number of CVT occurences after Pfizer to be even lower. In addition they will mostly be health care workers, at greater exposure to catching COVID-19, so it's possible that some were already infected (but asymptomatic) before they received the vaccine, which might have been the trigger for the event, as blood-clotting is a known clinical symptom of COVID-19.
Note that, because of the early uber-precautionary approach (there was insufficient evidence directly from the Phase 2 RCT trial that the vaccine is safe for over 65s) all the Ox-AZ vaccine in some countries (eg Germany) was used for health care workers and CEV under 65s - using Pfizer and a little Moderna for over 65s. In that younger cohort there is a preponderance of females. In Germany and France (say) only a minority in that cohort will have received Pfizer.
Earlier this month the UK reported some post vaccination events like this: they were evenly split between Pfizer and Ox-AZ vaccine recipients (11-13 iirc). The UK had not differentiated in age or cohort terms with the two vaccine makes. The incidence was at the same level that one would expect in normal times aiui.